Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Gene Therapy is Scopus-indexed (Q1, CiteScore 10.1), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Nature.
Checked against the index lists dated .
ISSN 0969-7128Verify ISSN ↗1476-5462Verify ISSN ↗
Publisher: Springer Nature
Cost to publish: About US$3,790 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Genetics | 30 / 357 | 91st | Q1 |
| Molecular Biology | 64 / 414 | 84th | Q1 |
| Molecular Medicine | 31 / 179 | 82nd | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1994–present, best quartile Q1, CiteScore 10.1.
Gene Therapy is Q1 in Genetics (rank 30 of 357), Q1 in Molecular Biology (rank 64 of 414) and Q1 in Molecular Medicine (rank 31 of 179), by CiteScore 2025.
Gene Therapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 10.1, which places it in quartile Q1 at the 91st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.502, quartile Q1, with an H-index of 181.
The publisher lists an article processing charge of about US$3,790 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Gene Therapy is published by Springer Nature. Its print ISSN is 0969-7128 and its online ISSN is 1476-5462.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Gene Therapy has an h-index of 191 and a 2-year mean of 4.26 citations per paper (OpenAlex). Its Scopus CiteScore is 10.1, quartile Q1. On 2-year citations it ranks #78 of 353 Scopus journals in Genetics.
Gene Therapy published 74 papers in 2025; its busiest recent year was 2020 with 112. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2025–2026), authors are most often from United States (30.9%), China (14.2%) and United Kingdom (8.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 22 retracted papers are recorded (4.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.